Spots Global Cancer Trial Database for biliary cancer
Every month we try and update this database with for biliary cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers | NCT00626158 | Pancreatic Canc... Biliary Cancer | gemcitabine capecitabine | 18 Years - | University of California, San Francisco | |
| Perception Prognosis, Goals of Treatment, and Communication | NCT01401894 | Gastric Cancer Esophageal Canc... Pancreatic Canc... Liver Cancer Biliary Cancer | 18 Years - | Massachusetts General Hospital | ||
| A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma | NCT03609489 | Biliary Carcino... | Capecitabine Apatinib | 18 Years - 75 Years | First Affiliated Hospital of Guangxi Medical University | |
| Neoadjuvant Therapy in Biliary Adenocarcinoma | NCT04480190 | Cholangiocarcin... Biliary Cancer | Gemcitabine Cisplatin Fluorouracil Short course Ch... | 18 Years - | University of Cincinnati | |
| Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors | NCT00551096 | Malignant Solid... Biliary Cancer Pancreatic Canc... | Gemcitabine Capecitabine ZD6474 | 18 Years - | University of Colorado, Denver | |
| Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer | NCT01773785 | Biliary Cancer | SPI-1620 Docetaxel | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations | NCT04087876 | Intrahepatic Ch... | derazantinib | 18 Years - | Basilea Pharmaceutica | |
| IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread | NCT01099631 | Cancer of the L... Liver Cancer Hepatoma Liver Neoplasms Biliary Cancer | Salmonella typh... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer | NCT04005339 | Advanced Biliar... | Nanoliposomal I... Leucovorin Fluorouracil | 18 Years - | Georgetown University | |
| Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary Cancer | NCT02479984 | Pancreatic Canc... | Staging Laparos... Laparoscopic ul... | 15 Years - 80 Years | National Cancer Center, Korea | |
| GTX Regimen for Biliary Cancers | NCT00868998 | Biliary Cancer | Gemcitabine, do... | 18 Years - | Columbia University | |
| Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy | NCT04517448 | Colorectal Canc... Pancreatic Canc... Biliary Cancer Hepatic Cancer Oesophageal Can... Gastric Cancer | 75 Years - | Centre Hospitalier de la côte Basque | ||
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | NCT04566133 | Bile Duct Cance... Biliary Cancer Biliary Tract N... Cholangiocarcin... | Trametinib Hydroxychloroqu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | NCT04644068 | Ovarian Cancer Breast Cancer Pancreatic Canc... Prostate Cancer Additional Indi... Non-small Cell ... Colorectal Canc... Bladder Cancer Gastric Cancer Biliary Cancer Cervical Cancer Endometrial Can... Small Cell Lung... | AZD5305 Paclitaxel Carboplatin T- Dxd Dato-DXd Camizestrant | 18 Years - 130 Years | AstraZeneca | |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | NCT05592626 | Advanced Solid ... Genital Neoplas... Urogenital Neop... Lung Neoplasm Neoplasms by Si... Papillomavirus ... Epstein-Barr Vi... Carcinoma Neoplasms Vulvar Neoplasm... Vulvar Diseases Abdominal Neopl... | STAR0602 | 18 Years - | Marengo Therapeutics, Inc. | |
| Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection | NCT05517811 | Liver Cancer Esophageal Canc... Colorectal Canc... Lung Adenocarci... Control Pancreas Cancer Biliary Cancer | TEG indices | 18 Years - 99 Years | University of Colorado, Denver | |
| Postoperative Oral Nutritional Supplementation After Major Gastrointestinal Surgery | NCT01838109 | Gastric Cancer Colon Cancer Pancreatic Canc... Duodenal Cancer Biliary Cancer Peptic Ulcer Inflammatory Bo... | oral nutritiona... | 20 Years - 80 Years | Seoul National University Hospital | |
| A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | NCT02576431 | Solid Tumors Ha... | BAY2757556 (Lar... | 18 Years - | Bayer | |
| Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures. | NCT02930252 | Biliary Cancer | Niti-S Biliary ... Niti-S stent (D... | 18 Years - | Azienda USL 1 Imperiese | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer | NCT01859728 | Biliary Cancer | Irinotecan Cisplatin Cisplatin Gemcitabine | 18 Years - | Barretos Cancer Hospital | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | NCT05849480 | Biliary Cancer Bile Duct Cance... Cancer of the B... | oxaliplatin capecitabine Keytruda CDX-1140 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma | NCT00948935 | Biliary Cancer Cholangiocarcin... | Gemcitabine, Ir... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Tremelimumab With Chemoembolization or Ablation for Liver Cancer | NCT01853618 | Heptocellular C... Biliary Tract N... Liver Cancer Hepatocellular ... Biliary Cancer | Tremelimumab RFA TACE Cryoablation | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer | NCT02908451 | Gastric Cancer Colorectal Canc... Pancreatic Canc... Biliary Cancer | AbGn-107 | 18 Years - | AbGenomics B.V Taiwan Branch | |
| Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection | NCT05517811 | Liver Cancer Esophageal Canc... Colorectal Canc... Lung Adenocarci... Control Pancreas Cancer Biliary Cancer | TEG indices | 18 Years - 99 Years | University of Colorado, Denver | |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | NCT04566133 | Bile Duct Cance... Biliary Cancer Biliary Tract N... Cholangiocarcin... | Trametinib Hydroxychloroqu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | NCT05849480 | Biliary Cancer Bile Duct Cance... Cancer of the B... | oxaliplatin capecitabine Keytruda CDX-1140 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | NCT02091141 | Neoplasms Solid Tumors Biliary Cancer Salivary Cancer Bladder Cancer | Trastuzumab Pertuzumab Erlotinib Vemurafenib Cobimetinib Vismodegib Alectinib Atezolizumab | 18 Years - | Genentech, Inc. | |
| Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary Cancer | NCT02479984 | Pancreatic Canc... | Staging Laparos... Laparoscopic ul... | 15 Years - 80 Years | National Cancer Center, Korea | |
| Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) | NCT06101277 | Esophageal Canc... Small Bowel Can... Gastroesophagea... Gastric Cancer Colorectal Canc... Appendiceal Can... Biliary Cancer Gall Bladder Ca... Intrahepatic Ch... Extrahepatic Ch... Oligoprogressiv... | Ablative local ... | 18 Years - | University of California, Davis | |
| A Study of Patients Receiving High-Dose Rate Brachytherapy | NCT00924027 | Cervical Cancer Endometrial Can... Esophageal Canc... Prostate Cancer Biliary Cancer | HDR Brachythera... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma | NCT01375972 | Metastatic Bili... | S-1 plus cispla... Gemcitabine plu... | 18 Years - | Asan Medical Center | |
| Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers | NCT00626158 | Pancreatic Canc... Biliary Cancer | gemcitabine capecitabine | 18 Years - | University of California, San Francisco | |
| A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma | NCT03609489 | Biliary Carcino... | Capecitabine Apatinib | 18 Years - 75 Years | First Affiliated Hospital of Guangxi Medical University | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
